​

AnaptysBio (ANAB) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChart

ANAB Stock Forecast

AnaptysBio (ANAB) stock forecast, based on 19 Wall Street analysts, predicts a 12-month average price target of $35.25, with a high of $52.00 and a low of $19.00. This represents a 71.53% increase from the last price of $20.55.

$10 $19 $28 $37 $46 $55 High: $52 Avg: $35.25 Low: $19 Last Closed Price: $20.55

ANAB Stock Rating

AnaptysBio stock's rating consensus is Buy, based on 19 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 11 Buy (57.89%), 8 Hold (42.11%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 19 0 8 11 Strong Sell Sell Hold Buy Strong Buy

ANAB Price Target Upside V Benchmarks

TypeNameUpside
StockAnaptysBio71.53%
SectorHealthcare Stocks 35.25%
IndustryBiotech Stocks 86.56%

Price Target Trends

1M3M12M
# Anlaysts-29
Avg Price Target-$38.50$47.56
Last Closing Price$20.55$20.55$20.55
Upside/Downside-87.35%131.44%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Apr, 25273--12
Mar, 25273--12
Feb, 25273--12
Jan, 25263--11
Dec, 24374--14
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Mar 03, 2025Guggenheim$52.00$14.64255.19%153.04%
Feb 04, 2025Andy ChenWolfe Research$25.00$16.6650.06%21.65%
Dec 11, 2024Emily BodnarH.C. Wainwright$19.00$15.5122.50%-7.54%
Nov 06, 2024Emily BodnarH.C. Wainwright$52.00$19.38168.32%153.04%
Nov 06, 2024David RisingerLeerink Partners$45.00$19.38132.20%118.98%
Oct 21, 2024Yatin SunejaGuggenheim$90.00$34.98157.29%337.96%
Oct 15, 2024Yasmeen RahimiPiper Sandler$80.00$34.74130.28%289.29%
Oct 03, 2024David RisingerNew Street$35.00$35.22-0.62%70.32%
Aug 15, 2024Joon LeeTruist Financial$30.00$34.65-13.42%45.99%
Apr 16, 2024David RisingerLeerink Partners$47.00$21.27120.97%128.71%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Mar 26, 2025Johnson RiceBuyBuyhold
Mar 03, 2025GuggenheimBuyBuyhold
Feb 03, 2025Wolfe ResearchOutperforminitialise
Dec 11, 2024H.C. WainwrightBuyNeutraldowngrade
Dec 02, 2024BTIGNeutraldowngrade
Oct 30, 2024H.C. WainwrightBuyBuyhold
Oct 21, 2024WedbushBuyBuyhold
Oct 21, 2024GuggenheimBuyBuyhold
Oct 15, 2024Piper SandlerOverweightOverweighthold
Oct 03, 2024Leerink PartnersOutperformOutperformhold

Financial Forecast

EPS Forecast

$-15 $-11 $-7 $-3 $1 $5 Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-0.73$-2.08$-4.57$-6.08$-5.12----
Avg Forecast$0.04$-1.83$-4.53$-6.07$-6.08$-5.36$-5.35$-5.76$-5.69
High Forecast$0.06$-0.60$-1.76$-5.95$-5.70$-3.66$-2.69$-1.92$0.16
Low Forecast$0.01$-2.67$-8.20$-6.32$-6.22$-7.28$-8.61$-10.23$-13.73
Surprise %-1925.00%13.66%0.88%0.16%-15.79%----

Revenue Forecast

$0 $40M $80M $120M $160M $200M Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$75.00M$63.17M$10.29M$17.16M$91.28M----
Avg Forecast$95.00M$63.17M$9.05M$11.94M$55.92M$35.45M$45.32M$60.90M$79.97M
High Forecast$128.49M$85.43M$14.70M$14.69M$73.19M$73.97M$46.07M$127.08M$166.87M
Low Forecast$45.91M$30.52M$4.80M$6.09M$45.09M$7.39M$44.57M$12.70M$16.68M
Surprise %-21.05%0.01%13.64%43.67%63.24%----

Net Income Forecast

$-400M $-310M $-220M $-130M $-40M $50M Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-19.92M$-57.19M$-128.72M$-163.62M$-145.23M----
Avg Forecast$-12.30M$-49.34M$-26.58M$-163.62M$-165.66M$-184.77M$-204.22M$-233.66M$-153.20M
High Forecast$5.46M$-16.19M$-6.96M$-42.85M$-153.58M$-98.59M$-72.41M$-51.69M$4.42M
Low Forecast$-30.06M$-71.95M$-46.20M$-284.39M$-167.59M$-196.12M$-231.86M$-275.43M$-369.63M
Surprise %61.95%15.92%384.26%--12.33%----

ANAB Forecast FAQ

Is AnaptysBio stock a buy?

AnaptysBio stock has a consensus rating of Buy, based on 19 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 11 Buy, 8 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that AnaptysBio is a favorable investment for most analysts.

What is AnaptysBio's price target?

AnaptysBio's price target, set by 19 Wall Street analysts, averages $35.25 over the next 12 months. The price target range spans from $19 at the low end to $52 at the high end, suggesting a potential 71.53% change from the previous closing price of $20.55.

How does AnaptysBio stock forecast compare to its benchmarks?

AnaptysBio's stock forecast shows a 71.53% upside, outperforming the average forecast for the healthcare stocks sector (35.25%) and underperforming the biotech stocks industry (86.56%).

What is the breakdown of analyst ratings for AnaptysBio over the past three months?

  • April 2025: 16.67% Strong Buy, 58.33% Buy, 25.00% Hold, 0% Sell, 0% Strong Sell.
  • March 2025: 16.67% Strong Buy, 58.33% Buy, 25.00% Hold, 0% Sell, 0% Strong Sell.
  • February 2025: 16.67% Strong Buy, 58.33% Buy, 25.00% Hold, 0% Sell, 0% Strong Sell.

What is AnaptysBio’s EPS forecast?

AnaptysBio's average annual EPS forecast for its fiscal year ending in December 2025 is $-5.36, marking a 4.69% increase from the reported $-5.12 in 2024. Estimates for the following years are $-5.35 in 2026, $-5.76 in 2027, and $-5.69 in 2028.

What is AnaptysBio’s revenue forecast?

AnaptysBio's average annual revenue forecast for its fiscal year ending in December 2025 is $35.45M, reflecting a -61.17% decrease from the reported $91.28M in 2024. The forecast for 2026 is $45.32M, followed by $60.9M for 2027, and $79.97M for 2028.

What is AnaptysBio’s net income forecast?

AnaptysBio's net income forecast for the fiscal year ending in December 2025 stands at $-185M, representing an 27.22% increase from the reported $-145M in 2024. Projections indicate $-204M in 2026, $-234M in 2027, and $-153M in 2028.